SUMMARY: After preliminary experiments were done on the pharmacologic properties of the neuroleptanalgesic drug combination of etorphine and acepromazine in dogs, the clinical pharmacology of the drug was studied in the horse. Adequate doses of the preparation (expressed in terms of etorphine: 7.5 μg./kg. in dogs and 15 to 25 μg./kg. in horses) provided excellent analgesia in both species. Predominating side effects in the dog were hypotension, bradycardia, and respiratory depression, all of which were due to etorphine, and an α-adrenolytic effect for which acepromazine was responsible. In the horse, analgesia was accompanied by signs of a strong nicotine-like excitation: muscular tremor and rigidity, mydriasis, sweating, and pronounced hypertension and tachycardia. Besides, respiratory depression was apparent, and a long-lasting paralysis of intestinal peristalsis and anorexia were noticed. Diprenorphine was a reliable antagonist of the etorphine component in both species. The serious side effects of the drug combination should preclude its use for neuroleptanalgesia in the horse.